Expression of tumor‐associated 90k‐antigen in human breast cancer: No correlation with prognosis and response to first‐line therapy with tamoxifen
暂无分享,去创建一个
J. Foekens | M. Look | H. Portengen | W. van Putten | C. Natoli | S. Lacobelli | Pia Di Stefano | Jan G. M. Klun | P. Stefano
[1] J. Foekens,et al. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. , 1994, British Journal of Cancer.
[2] J. Foekens,et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Ullrich,et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. , 1994, The Journal of biological chemistry.
[4] I. Ellis,et al. Transforming Growth Factor-α and Endocrine Sensitivity in Breast Cancer , 1994 .
[5] P. Sismondi,et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. , 1994, British Journal of Cancer.
[6] Giampietro Gasparini,et al. Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,” , 1993 .
[7] J. Goedert,et al. A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. , 1993, AIDS research and human retroviruses.
[8] J. Foekens,et al. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Foekens,et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.
[10] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Cairns,et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.
[12] N. Piggott,et al. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. , 1991, British Journal of Cancer.
[13] M. Freeman,et al. An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Farndon,et al. EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.
[15] S. Iacobelli,et al. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. , 1986, Cancer research.
[16] K. Horwitz,et al. Progestin action and progesterone receptor structure in human breast cancer: a review. , 1985, Recent progress in hormone research.
[17] W. McGuire,et al. The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.